Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition
Journal for ImmunoTherapy of Cancer · 2023-10 · 11 (10) · e007230
DOI: 10.1136/jitc-2023-007230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 06.10.2023. Verfasst von Anze Yu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, the Natural Science Foundation of Guangdong Province, China, Guangzhou Science and Technology Projects.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitor (ICI) therapy improves the survival of patients with advanced bladder cancer (BLCA); however, its overall effectiveness is limited, and many patients still develop immunotherapy resistance. The leucine-rich repeat and fibronectin type-III domain-containing protein (LRFN) family has previously been implicated in regulating brain dysfunction; however, the mechanisms underlying the effect of LRFN2 on the tumor microenvironment (TME) and immunotherapy remain unclear.
Methods
Here we combined bulk RNA sequencing, single-cell RNA sequencing, ProcartaPlex multiple immunoassays, functional experiments, and TissueFAXS panoramic tissue quantification assays to demonstrate that LRFN2 shapes a non-inflammatory TME in BLCA.
Results
First, comprehensive multiomics analysis identified LRFN2 as a novel immunosuppressive target specific to BLCA. We found that tumor-intrinsic LRFN2 inhibited the recruitment and functional transition of CD8 + T cells by reducing the secretion of pro-inflammatory cytokines and chemokines, and this mechanism was verified in vitro and in vivo. LRFN2 restrained antitumor immunity by inhibiting the infiltration, proliferation, and differentiation of CD8 + T cells in vitro. Furthermore, a spatial exclusivity relationship was observed between LRFN2 + tumor cells and CD8 + T cells and cell markers programmed cell death-1 (PD-1) and T cell factor 1 (TCF-1). Preclinically, LRFN2 knockdown significantly enhanced the efficacy of ICI therapy. Clinically, LRFN2 can predict immunotherapy responses in real-world and public immunotherapy cohorts. Our results reveal a new role for LRFN2 in tumor immune evasion by regulating chemokine secretion and inhibiting CD8 + T-cell recruitment and functional transition.
Conclusions
Thus, LRFN2 represents a new target that can be combined with ICIs to provide a potential treatment option for BLCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China.
- Department of Urology, Xiangya Hospital Central South University, Changsha, Hunan, China.
- Department of Breast Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China.
- Department of Urology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China luojunh@mail.sysu.edu.cn zuxbxy@csu.edu.cn chenzhh75@mail.sysu.edu.cn.
- Department of Urology, Xiangya Hospital Central South University, Changsha, Hunan, China luojunh@mail.sysu.edu.cn zuxbxy@csu.edu.cn chenzhh75@mail.sysu.edu.cn.
ORCID-Profile: Zhenhua Chen, Xiongbing Zu, Junhang Luo
Förderung
- National Natural Science Foundation of China
- the Natural Science Foundation of Guangdong Province, China
- Guangzhou Science and Technology Projects
- Hunan Province Young Talents Program
- Hunan Natural Science Foundation
Zitieren
APA
Yu, A., Hu, J., Fu, L., Huang, G., Deng, D., Zhang, M., Wang, Y., Shu, G., Jing, L., Li, H., Chen, X., Yang, T., Wei, J., Chen, Z., Zu, X., & Luo, J. (2023). Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition. Journal for ImmunoTherapy of Cancer, 11(10), e007230. https://doi.org/10.1136/jitc-2023-007230
Vancouver
Yu A, Hu J, Fu L, Huang G, Deng D, Zhang M, et al. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition. Journal for ImmunoTherapy of Cancer. 2023;11(10):e007230. doi:10.1136/jitc-2023-007230
BibTeX
@article{Yu2023,
author = {Yu, Anze and Hu, Jiao and Fu, Liangmin and Huang, Gaowei and Deng, Dingshan and Zhang, Mingxiao and Wang, Yinghan and Shu, Guannan and Jing, Lanyu and Li, Huihuang and Chen, Xu and Yang, Taowei and Wei, Jinhuan and Chen, Zhenhua and Zu, Xiongbing and Luo, Junhang},
title = {Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {10},
pages = {e007230},
doi = {10.1136/jitc-2023-007230}
}
EUVIMED